Narcolepsy and cataplexy. Clinical features, treatment and cerebrospinal fluid findings.
D000328:Adult; D000661:Amphetamine / Q000627:therapeutic use; D001224:Aspartic Acid / Q000134:cerebrospinal fluid; D001835:Body Weight / Q000187:drug effects; D002385:Cataplexy / Q000134:cerebrospinal fluid / Q000188:drug therapy; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis; D003913:Dextroamphetamine / Q000627:therapeutic use; D004569:Electroencephalography; D001068:Feeding and Eating Disorders; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D007989:Libido / Q000187:drug effects; D008297:Male; D001523:Mental Disorders; D008715:Methionine / Q000134:cerebrospinal fluid; D008875:Middle Aged; D009290:Narcolepsy / Q000134:cerebrospinal fluid / Q000188:drug therapy; D010649:Phenylalanine / Q000134:cerebrospinal fluid; D013577:Syndrome; D014443:Tyrosine / Q000134:cerebrospinal fluid
D002556:Cerebrospinal Fluid Proteins; D001224:Aspartic Acid; D014443:Tyrosine; D010649:Phenylalanine; D008715:Methionine; D000661:Amphetamine; D003913:Dextroamphetamine; D006719:Homovanillic Acid